Germline pathogenic variants (PVs) in BRCA1 or BRCA2 (gBRCA1/2) are observed in 3% of unselected BC and in 10–15% of patients with triple-negative BC (TNBC) [2]. Here, BRCA2 is linked to breast cancer.